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Omega-3 fatty acids decrease 
oxidative stress and inflammation 
in macrophages from patients with 
small abdominal aortic aneurysm
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Anna Kuballa1, Jonathan Golledge5,6, Tom G. Bailey2,7, Christopher D. Askew2 & 
Fraser D. Russell1,2
Abdominal aortic aneurysm (AAA) is associated with inflammation and oxidative stress, the 
latter of which contributes to activation of macrophages, a prominent cell type in AAA. Omega-3 
polyunsaturated fatty acids (n-3 PUFAs) have been reported to limit oxidative stress in animal models 
of AAA. The aim of this study was to evaluate the effect of the n-3 PUFA docosahexaenoic acid (DHA) 
on antioxidant defence in macrophages from patients with AAA. Cells were obtained from men with 
small AAA (diameter 3.0–4.5 cm, 75 ± 6 yr, n = 19) and age- matched male controls (72 ± 5 yr, n = 41) 
and incubated with DHA for 1 h before exposure to 0.1 µg/mL lipopolysaccharide (LPS) for 24 h. 
DHA supplementation decreased the concentration of tumour necrosis factor-α (TNF-α; control, 
42.1 ± 13.6 to 5.1 ± 2.1 pg/ml, p < 0.01; AAA, 25.2 ± 9.8 to 1.9 ± 0.9 pg/ml, p < 0.01) and interleukin-6 
(IL-6; control, 44.9 ± 7.7 to 5.9 ± 2.0 pg/ml, p < 0.001; AAA, 24.3 ± 5.2 to 0.5 ± 0.3 pg/ml, p < 0.001) 
in macrophage supernatants. DHA increased glutathione peroxidase activity (control, 3.2 ± 0.3 to 
4.1 ± 0.2 nmol/min/ml/μg protein, p = 0.004; AAA, 2.3 ± 0.5 to 3.4 ± 0.5 nmol/min/ml/μg protein, 
p = 0.008) and heme oxygenase-1 mRNA expression (control, 1.5-fold increase, p < 0.001). The 
improvements in macrophage oxidative stress status serve as a stimulus for further investigation of 
DHA in patients with AAA.
The long-chain omega-3 polyunsaturated fatty acids (n-3 PUFAs), docosahexaenoic acid (22:6n-3; DHA) and 
eicosapentaenoic acid (20:5n-3, EPA), have been suggested to have cardioprotective1,2, anti-inflammatory3, 
immunoregulatory4, antioxidant5,6 and anti-tumour activities7. These beneficial effects on human health have 
been attributed to (a) competition with arachidonic acid (AA) for the enzymes involved in the biosynthesis of 
pro-inflammatory mediator molecules8, (b) suppression of pro-inflammatory nuclear factor kappa B (NF-κ B) via 
modulation of toll-like receptor 4 (TLR4) signalling9 and activation of peroxisome proliferator-activated receptor 
gamma (PPAR γ)10, (c) activation of the G-protein-coupled receptor free fatty acid receptor 4 (FFA4, formerly 
GPR120)11 and d) metabolism to pro-resolution lipid mediators (e.g. resolvins, protectins, maresins)12,13. In syn-
ergism with their anti-inflammatory and pro-resolution activities, n-3 PUFAs have recently been documented to 
suppress pro-oxidant activity by upregulating genes encoding cytoprotective antioxidant proteins such as heme 
oxygenase 1 (HO-1) and glutathione peroxidase (GPx)14–16. HO-1 is a single, transmembrane 32-kDa protein that 
plays a central role in stress adaptation17. HO-1 provides cells and tissues with an inducible antioxidant defence 
mechanism that can be ubiquitously activated in response to elevated levels of heme, its natural substrate, and a 
multiplicity of endogenous factors such as heavy metals, cytokines, hormones, growth factors, nitric oxide and 
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endotoxins17. The enzyme’s robust ability to defend against oxidative insults is linked to the removal of reactive, 
pro-oxidant heme and to the biological effects of biliverdin, bilirubin, and carbon monoxide, the three reaction 
products18. The GPx family includes eight phylogenetically related antioxidant enzymes (GPxs 1–8) with essen-
tial, location-specific physiological effects involving the reduction of H2O2 to water and the detoxification of 
organic hydroperoxides to their corresponding alcohols19. By readily decomposing peroxides generated under a 
variety of physiological conditions, GPx enzymes play a vital role in limiting the strength and extent of reactive 
oxygen signals and contribute importantly to oxidation-reduction homeostasis and cellular protection20.
While n-3 PUFAs have been suggested to limit adverse outcomes associated with inflammation, oxidative 
stress and disturbed antioxidant status, a deeper understanding of the therapeutic potential of these bioactive 
nutrients is required in patient populations with conditions characterised by inflammation and oxidative over-
load such as abdominal aortic aneurysm (AAA). This study aimed to evaluate the effect of DHA on antioxidant 
defence in macrophages from patients with and without AAA. The HO-1 inhibitor, SnPP (10 μM), and FFA4 
receptor antagonist, AH7614 (2 μM), were used to examine mechanisms underlying n-3 PUFA effects.
Results
DHA inhibited 8-isoprostane production. Incubation of cells with DHA decreased LPS-stimulated 
8-isoprostane production in a dose-dependent manner in macrophages from healthy control participants 
(Fig. 1A). The slope for non-DHA treated data (BSA diluent; R2 = 0.93) was 7.3-fold greater than that of the DHA 
80 μM data (R2 = 0.83, p = 0.002). Although LPS-stimulated 8-isoprostane production was suppressed in mac-
rophages from the AAA patient cohort, a trend towards a further decrease in 8-isoprostane levels was observed 
when these cells were incubated with DHA (Fig. 1B).
DHA uniformly inhibited cytokine production. DHA-supplemented macrophages from control partici-
pants produced lower levels of TNF-α (Fig. 2A; 20 μM p < 0.001, 80 μM p = 0.004), IL-6 (Fig. 2C; 20 μM p = 0.002, 
80 μM p < 0.001), IL-1 β (Fig. 2E; 20 μM p = 0.005, 80 μM p = 0.004) and IL-10 (Fig. 2I; 20 μM p = 0.004, 80 μM 
p = 0.002) compared to non-supplemented cells. In AAA patient macrophages, DHA supplementation sup-
pressed the production of TNF-α (Fig. 2B; 80 μM p = 0.006), IL-6 (Fig. 2D; 20 μM p < 0.001, 80 μM p < 0.001) and 
IL-10 (Fig. 2J; 20 μM p = 0.008, 80 μM p = 0.004). A non-significant decrease was observed for IL-1 β (Fig. 2E). 
DHA supplementation did not alter TGF-β levels in macrophages from either the control (Fig. 2G) or AAA 
(Fig. 2H) cohorts. The effects of oleic acid on cytokine levels were similar to those of DHA. While CHD was evi-
dent in two thirds of the AAA cohort, no significant difference in cytokine concentrations (IL-6, IL-1β, TNF-α, 
IL-10, TGF-β) was observed for these patients when compared to non-CHD patients.
DHA increased GPx activity in monocyte-derived macrophages. DHA supplementation had no 
effect on catalase activity in macrophages obtained from control (Fig. 3A) or AAA participants (Fig. 3B). GPx 
activity was significantly increased in control and AAA macrophages supplemented with 80 μM DHA (control 
Fig. 3C, p = 0.005; AAA, Fig. 3D, p = 0.008).
DHA increased HO-1 expression in monocyte-derived macrophages. DHA supplementation 
induced a 50% increase in HO-1 mRNA in non-stimulated macrophages (p < 0.001) and a trend for increase 
(39%) was observed in macrophages exposed to hemin and LPS (Fig. 4A). The induction of HO-1 in macrophages 
stimulated with hemin and LPS was accompanied by decreases in concentrations of 8-isoprostane in supernatants 
from these cells (p < 0.01; Fig. 4B).
Figure 1. Concentration of 8-isoprostane in supernatants of monocyte-derived macrophages obtained 
from control participants and AAA patients. Monocytes were isolated from whole blood, grown in culture 
and, following spontaneous differentiation into macrophages, exposed to a 24 h incubation with 0.1 μg/
ml lipopolysaccharide (LPS) prior to collection of the cells and supernatants. LPS-stimulated 8-isoprostane 
production (pg/ml), plotted against total number of circulating monocytes present in whole blood samples, 
was lower in AAA (B) compared to control macrophage supernatants (A). DHA decreased LPS-stimulated 
8-isoprostane production in a dose-dependent manner in control participant macrophages. A non-significant 
trend for decreased 8-isoprostane production was observed in macrophages from AAA patients.
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Figure 2. Cytokine concentrations in macrophage supernatants obtained from control participants and 
AAA patients. Control DHA-supplemented non-stimulated macrophages (20 μM n = 5–9; 80 μM, n = 7–10) 
produced lower levels of tumour necrosis factor alpha (TNF-α; A), interleukin-6 (IL-6; C), interleukin-1 β 
(IL-β; E) and interleukin-10 (IL-10; I) compared to non-supplemented macrophages. DHA supplementation 
of AAA non-stimulated patient macrophages (20 μM n = 6–7; 80 μM, n = 8–10) decreased the production of 
TNF-α (B), IL-6 (D) and IL-10 (J). A trend toward decreased levels of IL-β (F; 20 μM n = 7; 80 μM n = 10) was 
observed. Transforming growth factor-β (TGF-β) levels in both control (G) and AAA (H) macrophages were 
unaffected by DHA supplementation. *p < 0.05.
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DHA, SnPP and AH7614 did not adversely affect cell viability. U937 cell viability was determined 
in LPS-stimulated cells pre-treated with DHA and/or SnPP or AH7614 using the MTT assay. No adverse change 
in cell viability was detected for any of the treatment conditions at the concentrations used in this study (Table 1).
The protective effect of DHA was partially reversed by the heme oxygenase inhibitor 
SnPP. DHA supplementation decreased 8-isoprostane production in LPS-stimulated U937 cells (Fig. 5A), 
an effect that was not reversed by pre-treatment of the cells with the FFA4 antagonist AH7614 (Fig. 5B). 
Pre-treatment of cells with the heme oxygenase inhibitor SnPP increased 8-isoprostane production to a level 
above that of LPS alone (Fig. 5C). A trend for reduced 8-isoprostane levels was observed in LPS-stimulated cells 
treated with SnPP and DHA.
DHA exhibited modest free radical-scavenging activity. DHA and EPA exhibited modest scavenging 
activity for the stable DPPH free radical at 30 min (28% and 24% respectively) in comparison to positive controls 
(quercetin and BHT; Fig. 6). OA showed negligible free radical scavenging activity.
Discussion
Macrophages feature prominently in human and experimental AAA formation and growth. The use of mac-
rophages in this investigation contributed to the pre-clinical evaluation of n-3 PUFAs as a novel therapeutic strat-
egy in AAA and uncovered mechanisms underlying n-3 PUFA-mediated improvements in oxidative stress status. 
Supplementation with the n-3 PUFA, DHA, suppressed production of 8-isoprostane, the gold standard biomarker 
of oxidative stress and a specific marker of lipid peroxidation21, in monocyte-derived macrophages obtained from 
patients with AAA. The results concord with data from both experimental animal studies22,23 and human clinical 
trials24,25 that suggest n-3 PUFAs decrease 8-isoprostane levels and ease oxidative stress. Importantly, the decrease 
observed in levels of 8-isoprostane in supplemented monocyte-derived macrophages suggests highly unsaturated 
n-3 PUFAs such as DHA do not increase susceptibility to lipid peroxidation. This contention is supported by the 
Figure 3. Antioxidant enzyme activity levels in control participant and AAA patient monocyte-derived 
macrophage lysates. Macrophage catalase activity was unaffected by DHA supplementation in control 
participants (A) and AAA patients (B). DHA supplementation increased glutathione peroxidase (GPx) activity 
in non-stimulated macrophages from control participants (C) and patients with AAA (D). Catalase and GPx 
activity and expression levels were unaffected by supplementation with OA. *p < 0.05.
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results of a pre-clinical study that indicated n-3 PUFA-mediated improvements in murine redox status were a 
consequence of reduced omega-6 fatty acid peroxidation and diversion away from the peroxyl radical pathway 
of F2-isoprostane formation26. It is noteworthy that the LPS-stimulated 8-isoprostane response in AAA mac-
rophages was suppressed compared to control macrophages. This finding is in line with our previous report of an 
abrogated cytokine response to LPS in a AAA patient cohort, consistent with endotoxin tolerance27.
8-isoprostanes are stable, robust prostaglandin-like molecules formed independently of cyclooxygen-
ase enzymes as a consequence of reactive oxygen species (ROS)-mediated peroxidation of esterified ara-
chidonic acid28. Isoprostanes are released to their free acid form by phospholipase action and the activity of 
platelet-activating factor acetylhydrolase following their in situ generation from arachidonic acid29. Available 
evidence suggests quantification of these compounds accurately assesses total F2-isoprostane production and 
provides a highly precise time-integrated index of oxidation status21.
In addition to favourable impacts on multiple aspects of the oxidative stress response, n-3 PUFAs are 
well documented to down-regulate pro-inflammatory processes30,31 and to quench injury-, infection- and 
exercise-induced inflammatory conditions32,33. The mechanism for the anti-inflammatory effects of n-3 PUFAs 
has been attributed to activation of FFA4 receptors, resulting in preservation of inhibitor of κB (IκB) and preven-
tion of nuclear translocation of NFκB11. Our data showed DHA-supplemented macrophages from both control 
participants and patients with AAA produced lower levels of the pro-inflammatory cytokines TNF-α and IL-6 
in response to a pro-inflammatory stimulus. The anti-inflammatory and resolution-directed activities described 
for DHA represent an indirect mechanism by which n-3 PUFAs lower endogenous ROS and positively impact 
cellular redox status. Activated leukocytes are known to generate powerful oxidants during phagocytosis and to 
propagate a pro-oxidant milieu by producing cytokines (TNF-α, IL-6) that stimulate ROS generation by endothe-
lial cells and other leukocytes34. Omega-3 PUFA interference with pro-inflammatory pathways reduces leukocyte 
activity and decreases leukocyte-mediated ROS production to favourably impact oxidative stress status35.
Figure 4. Increase in HO-1 transcripts and decrease in 8-isoprostane concentration in monocyte-derived 
macrophages from control participants. Real-time quantitative PCR, with raw data normalised to GAPDH, 
indicated increased HO-1 expression levels in DHA-supplemented non-stimulated macrophages and a trend for 
increase in LPS-stimulated macrophages exposed to DHA (A). In parallel, significant decreases were observed 
in 8-isoprostane concentrations in supernatants from hemin- and LPS-stimulated macrophages (B). Values are 
mean ± SEM of duplicate determinations (n = 5). *p < 0.05.
Compound LPS-stimulated (% of control)
Albumin (control cells) 100
DHA 20 μM 109.04 ± 8.75
DHA 80 μM 99.71 ± 3.26
SnPP 10 μM 110.43 ± 4.80
SnPP 10 μM + DHA 20 μM 112.34 ± 6.63
SnPP 10 μM + DHA 80 μM 103.37 ± 5.91
AH7614 2 μM 110.58 ± 9.05
AH7614 2 μM + DHA 20 μM 120.52 ± 7.31
AH7614 2 μM + DHA 80 μM 105.12 ± 7.82
Table 1. Effect of DHA, SnPP and AH7614 on cell viability. Abbreviations: DHA – docosahexaenoic acid, SnPP 
– tin protoporphyrin.
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This study examined more direct mechanisms underlying n-3 PUFA-mediated improvements in oxidative 
stress by evaluating their impact on antioxidant enzymes and determining their capacity to scavenge ROS. 
Evidence of increased activity levels of GPx was found in non-stimulated macrophages treated with DHA in 
addition to increased levels of HO-1 mRNA in non-stimulated cells (50% increase) and a trend for increased 
levels in LPS-stimulated cells (39% increase). To investigate mechanisms underlying DHA-mediated suppression 
of 8-isoprostane production, additional experiments were carried out in a macrophage cell line. In these exper-
iments, exposure of U937 cells to the FFA4 receptor antagonist AH7614 failed to reverse the suppressive effects 
of DHA on macrophage 8-isoprostane formation. This finding suggests that the FFA4 receptor is not the effector 
protein in DHA-mediated improvements in oxidative stress status. In further experiments, exposure of U937 cells 
to the heme oxygenase inhibitor SnPP increased 8-isoprostane production to a level above that of LPS alone and a 
trend for reduced 8-isoprostane levels was observed in LPS-stimulated cells treated with SnPP and DHA. Failure 
of the HO-1 inhibitor to fully reverse the protective effects of DHA suggests that n-3 PUFAs decrease oxidative 
stress through multiple pathways. In support of this, and in synergism with their positive impacts on inflamma-
tion and cytoprotective enzymatic antioxidants, n-3 PUFAs were shown to exhibit a modest capacity to scavenge 
free radicals (DHA, 28%; EPA, 24%) in comparison to oleic acid, which had negligible free radical scavenging 
activity, and the positive controls quercetin and BHT which had high levels of free radical scavenging activity.
While an in vitro cell culture system is subject to inherent limitations, our use of native, non-immortalised 
and non-transformed primary cells allowed a biologically relevant representation of the unique responses of AAA 
and control macrophages to supplementation with DHA. It is of note that the results obtained for 8-isoprostane 
and GPx in supplemented monocyte-derived AAA macrophages mirror the results of a recent n-3 PUFA 
Figure 5. 8-Isoprostane levels in non-stimulated and LPS-stimulated U937 cells incubated in the presence 
and/or absence of DHA (20 μM; 80 μM), the FFA4 antagonist AH7614 and the HO-1 inhibitor SnPP. 
Supplementation of cells with DHA 80 μM decreased 8-isoprostane production (A), a finding that was not 
reversed with AH7614 treatment (B). In LPS-stimulated cells treated with SnPP (C), no significant effect 
was observed for DHA at either of the concentrations tested. Data are expressed as mean ± SEM and are 
representative of at least six independent experiments. *p < 0.05.
Figure 6. Free radical scavenging activity of quercetin 50 μM, BHT 227 μM, DHA 80 μM, EPA 80 μM and OA 
80 μM as measured by colorimetric 1,1-diphenyl-2-picrylhydrazyl (DPPH) assay. Quercetin and BHT were 
included as positive controls. Absorbance values for the diluent (BSA) were subtracted from all data sets. Data 
are expressed as mean ± SEM and are representative of four independent experiments.
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supplementation trial conducted by our group in a cohort of AAA patients (unpublished findings). While clinical 
evidence regarding n-3 PUFA efficacy in AAA patient populations is limited, low serum concentrations of n-3 
PUFAs have been associated with larger aneurysm size and a faster growth rate in a Japanese AAA cohort36. In 
addition, animal studies using an angiotensin II-infused ApoE−/− mouse model have reported decreased oxida-
tive stress signalling and reduced matrix metalloproteinase expression following n-3 PUFA supplementation37,38. 
Further long-term clinical studies will be required to determine whether n-3 PUFA-mediated improvements in 
oxidative stress translate into positive alterations in the histopathologic appearance of AAA at the level of the 
aorta.
Taken together, the findings of this study suggest the antioxidant potential of n-3 PUFAs arises from their abil-
ity, via multiple means, to lower endogenous ROS levels and positively impact cellular redox status. In addition 
to direct ROS scavenging, n-3 PUFAs suppress pro-inflammatory cytokine signalling and induce and/or activate 
cytoprotective antioxidant enzymes. Given the critical role of macrophages in the development and progression 
of AAA disease, the positive impact of DHA on macrophage pro-inflammatory responses serves as a stimulus for 
further investigation of this fatty acid in patients with AAA.
Materials and Methods
Participants. Patients with AAA were recruited from Sunshine Coast public and private clinics (Table 2). 
Control participants included members of the University of the Third Age and the general population of the 
Sunshine Coast, Queensland. The study was approved by the University of the Sunshine Coast (A/13/473 and 
A/16/833) and the Prince Charles Hospital Human Research Ethics Committees (HREC/12/QPCH/13). All 
experiments were performed in accordance with relevant guidelines and regulations. Written informed consent 
was obtained for each participant and all consented participants completed the study. The patient group included 
19 men with AAA (mean maximal diameter 37.8 ± 5.3 mm) and the control group included 41 men without a 
documented AAA. AAA is known to be much more common in men than in women39 and male gender is associ-
ated with a 4-fold higher risk of AAA40. In addition, we have reported recently that differences exist in erythrocyte 
fatty acid incorporation for men and women41. While cells were obtained from all participants, limited superna-
tant volumes precluded their inclusion in all experimental assays. Aneurysm size, evaluated as part of routine care 
and AAA surveillance, was confirmed with transabdominal ultrasound. Exclusion criteria for AAA patients and 
control participants included: age below 60 or above 86 years, BMI above 39 kg m−2, uncontrolled hypertension, 
cardiac arrhythmia, heart failure, symptomatic aortic stenosis, chronic obstructive pulmonary disease, chronic 
inflammatory disease and regular use of prescription anti-inflammatory medication. A family history of AAA or 
known aneurysmal disease served as additional exclusion criteria for control participants. Dietary and medical 
history questionnaires were used to ensure adherence to inclusion/exclusion criteria. All participants refrained 
from non-prescribed anti-inflammatory medications 72 h prior to blood collection and abstained from alcohol 
and caffeine for the 12 h leading up to their study visit.
Variable
AAA Patients 
(n = 19)
Control Participants 
(n = 41)
Age (years) 74.6 ± 5.8 71.9 ± 5.1
Smoking:
  Never 7 (37%) 17 (41%)
  Past 10 (53%) 24 (59%)
  Current 2 (11%) 0 (0%)
BMI (kg.m2) 26.9 ± 2.9 26.0 ± 4.1
Systolic blood pressure (mmHg) 136.5 ± 13.6 137.92 ± 13.2
Diastolic blood pressure (mmHg) 78.6 ± 6.1 79.4 ± 8.3
Hypertension 12 (63%) 15 (37%)
Diabetes 2 (11%) 0 (0%)
Coronary heart disease† 12 (63%) 4 (10%)
Medication
Low-dose aspirin 5 (26%) 3 (7%)
Anti-hypertensive agents:
  Beta blockers† 8 (42%) 5 (12%)
  Angiotensin II receptor antagonists 6 (32%) 7 (17%)
  ACE inhibitors 2 (11%) 3 (7%)
  Calcium channel blockers 2 (11%) 3 (7%)
  Diuretics 2 (11%) 2 (5%)
Statins† 14 (74%) 13 (32%)
Table 2. Demographic, biometric and medical characteristics of AAA patients and control participants 
(mean ± SD). †Significantly different to control (Fisher’s exact test, p < 0.05). AAA, abdominal aortic aneurysm; 
BMI, body mass index; NSAIDs, non-steroidal anti-inflammatory drugs.
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Fatty acid preparation. Fatty acids used in experiments included docosahexaenoic acid (C22:6n-3; DHA), 
eicosapentaenoic acid (C20:5n-3; EPA) and oleic acid (C18:1n-9; OA). Stock solutions (15 mM) of the fatty acids 
were prepared as previously described42. Control cells were supplemented with bovine serum albumin (BSA).
U937 cell culture and cell viability assay. Human myelo-monocytic lymphoma U937 cells (American 
Type Culture Collection, USA) were used in this study to uncover mechanisms underlying n-3 PUFA-mediated 
alterations in inflammatory and oxidative stress status. Immortalised macrophage-like cell lines offer the advan-
tages of ready availability and extensive proliferative potential and use of these cells allowed cellular responses 
to treatments to be studied under controlled conditions. U937 cells were maintained in RPMI 1640 medium 
(Sigma, USA) supplemented with 10% foetal calf serum (FCS; Gibco, USA), 1000 U/ml penicillin (Gibco, USA), 
and 1000 μg/ml streptomycin (Gibco, USA) in 25 cm2 or 75 cm2 tissue culture flasks (Corning, USA) at 37 °C 
humidified atmosphere with 5% CO2 and sub-cultured every 4th or 5th day. Following growth to confluence, cells 
were seeded onto 24-well culture plates (Corning Costar, USA) at a density of 4 × 105 cells/well and differentiation 
was induced by exposure of cells to phorbol 12-myristate 13-acetate (PMA; Sigma, USA; 20 nM; 24 h). Cells were 
allowed to mature for a further 46–48 h in fresh complete medium prior to a 2 h exposure to the FFA4 receptor 
antagonist AH7614 (2 μM, n = 6) or the heme oxygenase inhibitor tin protoporphyrin (SnPP; 10 μM, n = 9). These 
concentrations of agents would be anticipated to inhibit 96.2% of FFA4 receptors43 and 99.9% of HO-144. Cells 
were incubated with media containing bovine serum albumin (80 μM, BSA, control cells), EPA (20 μM, n = 6; 
80 μM, n = 6) or DHA (20 μM, n = 6; 80 μM, n = 6) for a further 2 h. Treated U937 cells were exposed to lipopol-
ysaccharide from Escherichia coli (LPS; 0.1 μg/ml, Serotype 0111:B4; Sigma, USA) for 6 h followed by collection 
and centrifugation (10,000 × g, 5 min, 4 °C) of the supernatants. Supernatants used to measure 8-isoprostane 
were preserved with butylhydroxytoluene (BHT; 2.5 mg/ml) to prevent artefactual 8-isoprostane formation. Cell 
viability was measured after treatment with AH7614 and SnPP using a commercially available colorimetric Cell 
Proliferation (MTT) Kit (Roche Diagnostics, Germany) in accordance with manufacturer’s instructions.
Monocyte isolation protocol. Whole blood was collected in ethylenediaminetetraacetic acid (EDTA) 
tubes (4 × 6 ml) and centrifuged (400 × g, 25 min, 18 °C) with the brake turned off. The buffy coat was collected 
and diluted with 8 ml Ca2+/Mg2+-free Dulbecco’s phosphate buffered solution containing 1 mM EDTA (DPBS, 
pH 7.1) and centrifuged (150 × g, 18 °C, 10 min, brake off). The wash was repeated twice and the final spin was 
followed by removal of the supernatant and resuspension of cells with 1 ml of DPBS. Resuspended cells were 
layered to the surface of 2 ml aliquots of Ficoll-Paque Premium 1.073 (GE Healthcare, Sweden), the preparation 
was centrifuged (400 × g, 30 min, 18 °C) and cells within a dense white mononuclear band were collected and 
diluted with 5 ml DPBS. The cells were pelleted by centrifugation (500 × g, 10 min, 18 °C) and the supernatant 
was discarded. Monocyte purification was achieved by centrifugation with hyperosmotic Percoll Plus (Sigma, 
USA; prepared as per45) or by discontinuous density centrifugation using isotonic Percoll Plus at densities 1.070 g/
ml, 1.062 g/ml, 1.060 g/ml and 1.058 g/ml. The Percoll preparation was centrifuged (400 × g, 15 min, 21 °C) and 
monocytes within a band located at the interface of the Percoll solution and the DPBS/media were collected and 
diluted with 4 ml DPBS. The cells were pelleted by centrifugation (550 × g, 10 min, 21 °C) and the supernatant 
was discarded. An aliquot of the cell pellet (1 μl) was stained with May-Grunwald stain (Merck Millipore) to 
confirm the presence of monocytes. Monocytes were resuspended in 1 ml serum-free complete Iscove’s Modified 
Dulbecco’s Medium (IMDM) supplemented with 1000 U/ml penicillin (Gibco, USA), 1000 μg/ml streptomycin 
(Gibco, USA) and 2 mM L-glutamine (Gibco, USA) and cell number was determined using a haemocytometer.
Autologous serum preparation. Whole blood from each participant was collected in serum separator 
tubes (2 × 6 ml) and allowed to clot at 22 °C for 30 min prior to centrifugation (1500 × g, 15 min, 15 °C). The 
serum was collected, centrifuged (4000 × g, 5 min, 4 °C) and the supernatant was stored at −80 °C for use as an 
autologous serum supplement in cell cultures of isolated monocytes.
Monocyte culture. Monocytes were seeded onto 24 well culture plates (Corning Costar, USA) at a density 
of 3 × 105 cells/well (final volume 600 μl/well). Plated cells were transferred to a 37 °C humidified 5% CO2 incu-
bator for a period of 2 h, at which time the supernatant containing non-adherent cells was removed following 
gentle flushing and the medium was replaced with IMDM containing 5% autologous serum (v/v) and 50 ng/ml 
macrophage colony-stimulating factor (M-CSF, Sigma, USA). Further media changes occurred on days 1 and 4.
Macrophage maturation and activation. Monocytes matured into a morphologically heterogeneous 
macrophage population over 7 days. On day 7, the medium (IMDM and all additives except M-CSF) was replaced 
for a final time and the adherent macrophages were exposed to a 1 h treatment with BSA (control cells), DHA 
(20 μM or 80 μM) or OA (80 μM). The fatty acid concentrations used in the supplementation of cells have been 
documented to have no adverse effects on cell viability46,47 and have been shown to approximate the plasma DHA 
concentration, previously reported to be in the range of 91–122 μM48. To measure 8-isoprostane, treated cells were 
polarised toward an M1 phenotype through exposure to 20 ng/ml interferon gamma (IFN-γ) and 0.1 μg/ml LPS 
for a further 24 h. LPS is a well-characterised activator of TLR4, which is known to be expressed in human mac-
rophages. Elevated LPS levels have been associated with some AAA cases49,50, although this association remains 
a contentious issue51,52. All supernatants were collected, centrifuged (10,000 × g, 5 min, 4 °C) and aliquoted with 
and without BHT (2.5 mg/ml). For glutathione peroxidase (GPx) activity assays, a 300 μl aliquot of GPx collec-
tion buffer (50 mM Tris-HCl, pH 7.5, 5 mM EDTA, 1 mM DTT) was added to each well and adherent cells were 
harvested and stored at −80 °C. For catalase activity assays, a 300 μl aliquot of catalase collection buffer (50 mM 
KH2PO4, pH 7.0, containing 1 mM EDTA) was added to each well and adherent cells were harvested and stored 
at −80 °C.
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Measurement of free 8-isoprostane. To establish oxidative stress status, free 8-isoprostane levels were 
measured in BHT-preserved U937 and monocyte-derived macrophage supernatants without further manipula-
tion using a commercially available enzyme immunoassay kit (Cayman Chemical Company, Ann Arbor, USA) 
in accordance with manufacturer’s instructions. Samples were stored at −80 °C and assayed within 30 days of 
collection.
Cytokine assays. Cytokines (IL-6, TGF-β, TNF-α, IL-1β, IL-10) were measured in monocyte-derived mac-
rophage supernatants using commercially available enzyme immunoassay kits (Affymetrix eBioscience, San 
Diego, USA) in accordance with manufacturer’s instructions.
Antioxidant enzyme activity assays. GPx activity and catalase enzymatic activity was measured in 
monocyte-derived macrophage lysates using commercially available kits (Cayman Chemical Company, Ann 
Arbor, USA) in accordance with manufacturer’s instructions. Enzyme activity was expressed per μg protein53.
Free radical-scavenging activity assay. The free radical-scavenging activities of 80 μM DHA, EPA and 
OA were examined using a colorimetric 1,1-diphenyl-2picrylhydrazyl (DPPH) assay as previously described54. 
Briefly, fatty acids and positive controls (BHT 227 μM; quercetin 50 μM) were incubated with methanolic DPPH 
solutions (100 μM; 30 min; 22 °C) and absorbance was measured at 518 nm. A methanolic solution of DPPH 
(100 μM), decayed in the presence of 0.5 mM ascorbic acid to allow clearance of colour, was used for background 
correction. Results were expressed as percentage of a negative control using the following equation:
− = −







−
−



×




DPPH scavenging activity (%) 100 Blank adjusted absorbance of sample
Blank adjusted absorbance of negaticve control
100
RNA isolation and real-time quantitative PCR. Human blood derived monocytes were harvested and 
cultured as before. On day 7 of culture, adherent macrophages were exposed to a 1 h treatment with albumin 
(80 μM, control cells) or DHA (80 μM). Treated cells were incubated with hemin (20 μM; Sigma) and stimu-
lated with IFN-γ (20 ng/ml) and LPS (1 μg/ml) for 24 h to provoke super production of HO-155. Supernatants 
were collected, centrifuged and aliquoted as before. Cells were rinsed with DPBS and a 300 μl aliquot of 
RNALater RNA Stabilisation Reagent (Qiagen) was added to each well. Adherent cells were harvested by scrap-
ing and cells were cooled at 4 °C for 24 h followed by transfer to −20 °C for storage until analysis. Total RNA 
was extracted from samples using the Isolate II RNA mini kit (Bioline) prior to generation of cDNA using the 
SensiFAST cDNA synthesis kit (Bioline) and amplification of samples against transcripts by real-time quan-
titative PCR using the SensiMix SYBR No-Rox kit (Bioline) and a Rotor-Gene Q thermal cycler (Qiagen). 
Primers were from Sigma and included HO-1 forward 5′CCAGCAACAAAGTGCAAGATTC 3′, HO-1 reverse 
5′TCACATGGCATAAAGCCCTACAG 3′ 56 and GAPDH forward 5′GGGGGAGCCAAAAGGGTCATCATCT 
3′, GAPDH reverse 5′GAGGGGCCATCCACAGTCTTC3′ 57. No template controls were run in each reaction 
and no contamination was observed. Normalisation points included a) spectrophotometric RNA quantification 
(Nanodrop, ND100), b) inclusion of a reference sample in each run and c) determination of mRNA levels of an 
internal control (GAPDH) for all samples. Quantitation of relative gene expression was based on the comparative 
threshold cycle method (2−ΔΔCt)58 with raw data normalised to GAPDH.
Data analysis. Continuous demographic variables were compared using a student’s t-test and are presented 
as mean ± SD. Categorical demographic variables were compared using a Fisher’s exact test and data are presented 
as number (percentage). Experimental data are presented as mean ± SEM. Data were assessed to determine nor-
mality (Shapiro-Wilk test) and homogeneity of variance (Levene statistic). Where data followed Gaussian dis-
tribution, data were assessed using a student’s t-test, assuming equal or unequal variance as determined by the 
Levene statistic. Where the null hypothesis for the Shapiro-Wilk test was rejected, data were analysed using the 
Mann Whitney U test. Outliers in macrophage supernatant cytokine data (TNF-α n = 2, IL-6 n = 3, IL-10 n = 2 
and IL-1 β n = 2) were identified using the extreme studentised deviate many-outlier procedure59 and excluded 
from analysis. For U937 experiments, significance was determined using one-way ANOVA corrected for multiple 
comparisons with Sidak test. Statistical significance was set at p < 0.05.
References
 1. Burr, M. L. et al. Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial 
(DART). Lancet 2, 757–761 (1989).
 2. Wang, C. et al. n-3 Fatty acids from fish or fish-oil supplements, but not α-linolenic acid, benefit cardiovascular disease outcomes in 
primary-and secondary-prevention studies: a systematic review. Am. J. Clin. Nutr. 84, 5–17 (2006).
 3. Massaro, M. et al. The omega-3 fatty acid docosahexaenoate attenuates endothelial cyclooxygenase-2 induction through both NADP 
(H) oxidase and PKCε inhibition. Proc. Natl. Acad. Sci. 103, 15184–15189 (2006).
 4. Yang, Y.-C. et al. Docosahexaenoic acid inhibition of inflammation is partially via cross-talk between Nrf2/heme oxygenase 1 and 
IKK/NF-κB pathways. J. Nutr. Biochem. 24, 204–212 (2013).
 5. Carrepeiro, M. M. et al. Effect of n-3 fatty acids and statins on oxidative stress in statin-treated hypercholestorelemic and 
normocholesterolemic women. Atherosclerosis 217, 171–178 (2011).
 6. Bouzidi, N. et al. Effects of omega-3 polyunsaturated fatty-acid supplementation on redox status in chronic renal failure patients 
with dyslipidemia. J. Ren. Nutr. 20, 321–328 (2010).
 7. Calviello, G., Serini, S. & Palozza, P. n-3 polyunsaturated fatty acids as signal transduction modulators and therapeutical agents in 
cancer. Curr. Signal Transduct. Ther. 1, 255–271 (2006).
 8. Lands, W. Biochemistry and physiology of n-3 fatty acids. FASEB J. 6, 2530–2536 (1992).
 9. Lee, J. Y. et al. Differential modulation of Toll-like receptors by fatty acids preferential inhibition by n-3 polyunsaturated fatty acids. 
J. Lipid Res. 44, 479–486 (2003).
1 0Scientific RepoRtS |         (2019) 9:12978  | https://doi.org/10.1038/s41598-019-49362-z
www.nature.com/scientificreportswww.nature.com/scientificreports/
 10. Kliewer, S. A. et al. Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-
activated receptors α and γ. Proc. Natl. Acad. Sci. 94, 4318–4323 (1997).
 11. Oh, D. Y. et al. GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects. Cell 
142, 687–698 (2010).
 12. Serhan, C. Systems approach to inflammation resolution: identification of novel anti‐inflammatory and pro‐resolving mediators. J. 
Thromb. Haemost. 7, 44–48 (2009).
 13. Meital, L. T., Sandow, S. L., Calder, P. C. & Russell, F. D. Abdominal aortic aneurysm and omega-3 polyunsaturated fatty acids: 
Mechanisms, animal models, and potential treatment. Prostaglandins Leukot. Essent. Fatty Acids 118, 1–9 (2017).
 14. Zhang, M. et al. Omega-3 fatty acids protect the brain against ischemic injury by activating Nrf2 and upregulating heme oxygenase 
1. J. Neurosci. 34, 1903–1915 (2014).
 15. Kusunoki, C. et al. Omega-3 polyunsaturated fatty acid has an anti-oxidant effect via the Nrf-2/HO-1 pathway in 3T3-L1 adipocytes. 
Biochem. Biophys. Res. Commun. 430, 225–230 (2013).
 16. Ishikado, A. et al. 4-Hydroxy hexenal derived from docosahexaenoic acid protects endothelial cells via Nrf2 activation. PLoS ONE 
8, e69415 (2013).
 17. Origassa, C. & Camara, N. Cytoprotective role of heme oxygenase-1 and heme degradation derived end products in liver injury. 
World J. Hepatol. 5, 541–549 (2013).
 18. Abraham, N. G. & Kappas, A. Heme oxygenase and the cardiovascular-renal system. Free Radic. Biol. Med. 39, 1–25 (2005).
 19. Hawkes, W. C. & Alkan, Z. Regulation of redox signaling by selenoproteins. Biol. Trace Elem. Res. 134, 235–251 (2010).
 20. Lubos, E., Loscalzo, J. & Handy, D. E. Glutathione peroxidase-1 in health and disease: from molecular mechanisms to therapeutic 
opportunities. Antioxid. Redox. Signal. 15, 1957–1997 (2011).
 21. Kadiiska, M. et al. Biomarkers of oxidative stress study II: are oxidation products of lipids, proteins, and DNA markers of CCl 4 
poisoning? Free Radic. Biol. Med. 38, 698–710 (2005).
 22. Saraswathi, V. et al. Fish oil increases cholesterol storage in white adipose tissue with concomitant decreases in inflammation, 
hepatic steatosis, and atherosclerosis in mice. J. Nutr. 137, 1776–1782 (2007).
 23. Zúñiga, J. et al. Protection against in vivo liver ischemia-reperfusion injury by n-3 long-chain polyunsaturated fatty acids in the rat. 
Free Radic. Res. 44, 854–863 (2010).
 24. Mori, T. A. et al. Effect of eicosapentaenoic acid and docosahexaenoic acid on oxidative stress and inflammatory markers in treated-
hypertensive type 2 diabetic subjects. Free Radic. Biol. Med. 35, 772–781 (2003).
 25. Barden, A. E. et al. n-3 fatty acids reduce plasma 20-hydroxyeicosatetraenoic acid and blood pressure in patients with chronic kidney 
disease. J. Hypertens. 33, 1947–1953 (2015).
 26. Davis, T. A., Gao, L., Yin, H., Morrow, J. D. & Porter, N. A. In vivo and in vitro lipid peroxidation of arachidonate esters: the effect of 
fish oil ω-3 lipids on product distribution. J. Am. Chem. Soc. 128, 14897–14904 (2006).
 27. Russell, F. et al. Suppressed oxidative stress response in abdominal aortic aneurysm macrophages exposed to lipopolysaccharide. 
Australian Vascular Biology Society meeting, Hobart (2016).
 28. Morrow, J. D., Awad, J. A., Boss, H. J., Blair, I. A. & Roberts, L. J. Non-cyclooxygenase-derived prostanoids (F2-isoprostanes) are 
formed in situ on phospholipids. Proc. Natl. Acad. Sci. 89, 10721–10725 (1992).
 29. Milne, G. L., Dai, Q. & Roberts, L. J. The isoprostanes—25 years later. Biochim. Biophys. Acta 1851, 433–445 (2015).
 30. Ferguson, J. F. et al. Omega-3 polyunsaturated fatty acids attenuate inflammatory activation and alter differentiation in human 
adipocytes. J. Nutr. Biochem. 64, 45–49 (2019).
 31. Mocellin, M. C., Fernandes, R., Chagas, T. R. & Trindade, E. B. A meta-analysis of n-3 polyunsaturated fatty acids effects on 
circulating acute-phase protein and cytokines in gastric cancer. Clin. Nutr. 37, 840–850 (2018).
 32. Körner, A. et al. Resolution of inflammation and sepsis survival are improved by dietary Ω-3 fatty acids. Cell Death Differ. 25, 
421–431 (2018).
 33. Mickleborough, T. D., Sinex, J. A., Platt, D., Chapman, R. F. & Hirt, M. The effects PCSO-524®, a patented marine oil lipid and 
omega-3 PUFA blend derived from the New Zealand green lipped mussel (Perna canaliculus), on indirect markers of muscle 
damage and inflammation after muscle damaging exercise in untrained men: a randomized, placebo controlled trial. J. Int. Soc. 
Sports Nutr. 12, 10 (2015).
 34. Mori, T. A. Effect of fish and fish oil-derived omega-3 fatty acids on lipid oxidation. Redox Rep. 9, 193–197 (2013).
 35. Massaro, M., Scoditti, E., Carluccio, M. A. & De Caterina, R. Basic mechanisms behind the effects of n-3 fatty acids on cardiovascular 
disease. Prostaglandins Leukot. Essent. Fatty Acids 79, 109–115 (2008).
 36. Aikawa, T. et al. Low Serum Levels of EPA are Associated with the Size and Growth Rate of Abdominal Aortic Aneurysm. J. 
Atheroscler. Thromb. 24, 912–920 (2017).
 37. Wales, K. M. et al. N-3 PUFAs protect against aortic inflammation and oxidative stress in angiotensin II-infused apolipoprotein 
E−/− mice. PLoS ONE 9, e112816 (2014).
 38. Kavazos, K. et al. Dietary supplementation with omega-3 polyunsaturated fatty acids modulate matrix metalloproteinase 
immunoreactivity in a mouse model of pre-abdominal aortic aneurysm. Heart Lung Circ. 24, 377–385 (2015).
 39. Golledge, J., Muller, J., Daugherty, A. & Norman, P. Abdominal aortic aneurysm: pathogenesis and implications for management. 
Arterioscler. Thromb. Vasc. Biol. 26, 2605–2613 (2006).
 40. Kent, K. C. et al. Analysis of risk factors for abdominal aortic aneurysm in a cohort of more than 3 million individuals. J. Vasc. Surg. 
52, 539–548 (2010).
 41. Meital, L. T. et al. n-3 PUFAs improve erythrocyte fatty acid profile in patients with small AAA: a randomized controlled trial. J. 
Lipid Res. 60, 1154–1163 (2019).
 42. Tardivel, S. et al. Protective effects of EPA and deleterious effects of DHA on eNOS activity in Ea hy 926 cultured with 
lysophosphatidylcholine. Lipids 44, 225–235 (2009).
 43. Sparks, S. M. et al. Identification of diarylsulfonamides as agonists of the free fatty acid receptor 4 (FFA4/GPR120). Bioorg. Med. 
Chem. Lett. 24, 3100–3103 (2014).
 44. Drummond, G. S. & Kappas, A. Prevention of neonatal hyperbilirubinemia by tin protoporphyrin IX, a potent competitive inhibitor 
of heme oxidation. Proc. Natl. Acad. Sci. 78, 6466–6470 (1981).
 45. Meital, L. T. et al. A simple and effective method for the isolation and culture of human monocytes from small volumes of peripheral 
blood. J. Immunol. Methods 472, 75–78 (2019).
 46. Ambrozova, G., Pekarova, M. & Lojek, A. Effect of polyunsaturated fatty acids on the reactive oxygen and nitrogen species 
production by raw 264.7 macrophages. Eur. J. Nutr. 49, 133–139 (2010).
 47. Liu, Y. et al. The fish oil ingredient, docosahexaenoic acid, activates cytosolic phospholipase A2 via GPR120 receptor to produce 
prostaglandin E2 and plays an anti‐inflammatory role in macrophages. Immunology 143, 81–95 (2014).
 48. Marangoni, F. et al. Changes of n-3 and n-6 fatty acids in plasma and circulating cells of normal subjects, after prolonged 
administration of 20: 5 (EPA) and 22: 6 (DHA) ethyl esters and prolonged washout. Biochim. Biophys. Acta Lipids Lipid Metab. 1210, 
55–62 (1993).
 49. Vikatmaa, P. et al. Chlamydial lipopolysaccharide (cLPS) is present in atherosclerotic and aneurysmal arterial wall—cLPS levels 
depend on disease manifestation. Cardiovasc. Pathol. 19, 48–54 (2010).
 50. Juvonen, J. et al. Demonstration of Chlamydia pneumoniae in the walls of abdominal aortic aneurysms. J. Vasc. Surg. 25, 499–505 
(1997).
1 1Scientific RepoRtS |         (2019) 9:12978  | https://doi.org/10.1038/s41598-019-49362-z
www.nature.com/scientificreportswww.nature.com/scientificreports/
 51. Karlsson, L., Gnarpe, J., Bergqvist, D., Lindbäck, J. & Pärsson, H. The effect of azithromycin and Chlamydophilia pneumonia 
infection on expansion of small abdominal aortic aneurysms-A prospective randomized double-blind trial. J. Vasc. Surg. 50, 23–29 
(2009).
 52. Nyberg, A., Skagius, E., Nilsson, I., Ljungh, A. & Henriksson, A. E. Lack of association between Chlamydophila pneumoniae 
seropositivity and abdominal aortic aneurysm. Vasc. Endovascular Surg. 41, 246–248 (2007).
 53. Lowry, O., Rosebrough, N., Farr, A. & Randall, R. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193, 265–275 
(1951).
 54. Hamilton, K. D., Brooks, P. R., Ogbourne, S. M. & Russell, F. D. Natural products isolated from Tetragonula carbonaria cerumen 
modulate free radical-scavenging and 5-lipoxygenase activities in vitro. BMC Complement. Altern. Med. 17, 232 (2017).
 55. Srisook, K. et al. CO from enhanced HO activity or from CORM-2 inhibits both O 2− and NO production and downregulates HO-1 
expression in LPS-stimulated macrophages. Biochem. Pharmacol. 71, 307–318 (2006).
 56. Maruyama, A., Mimura, J., Harada, N. & Itoh, K. Nrf2 activation is associated with Z-DNA formation in the human HO-1 promoter. 
Nucleic Acids Res. 41, 5223–5234 (2013).
 57. Long, J., Zhao, J., Yan, Z., Liu, Z. & Wang, N. Antitumor effects of a novel sulfur‐containing hydroxamate histone deacetylase 
inhibitor H40. Int. J. Cancer 124, 1235–1244 (2009).
 58. Schmittgen, T. D. & Livak, K. J. Analyzing real-time PCR data by the comparative C T method. Nat. Protoc. 3, 1101–1108 (2008).
 59. Rosner, B. Percentage points for a generalized ESD many-outlier procedure. Technometrics 25, 165–172 (1983).
Acknowledgements
This work was supported by Wishlist – Sunshine Coast Health Foundation, The Cluster for Biomedical Innovation 
and the School of Health and Sport Science, University of the Sunshine Coast. JG holds a Practitioner Fellowship 
from the National Health and Medical Research Council (1117061) and a Senior Clinical Research Fellowship 
from the Queensland Government, Australia.
Author Contributions
Conception of the study (L.T.M., M.T.W., M.P., K.S., R.M., A.K., J.G., T.G.B., C.D.A., F.D.R.); Design of the study 
(L.T.M., A.K., C.D.A., F.D.R.); Sample acquisition (L.T.M., M.T.W., M.P., K.S., R.M., J.G., F.D.R.); Data acquisition 
(L.T.M., A.K., F.D.R.); Data analysis (L.T.M., A.K., T.G.B., C.D.A., F.D.R.); Data interpretation (L.T.M., A.K., J.G., 
T.G.B., C.D.A., F.D.R.); Manuscript preparation (L.T.M., A.K., J.G., T.G.B., C.D.A., F.D.R.).
Additional Information
Competing Interests: The authors declare no competing interests.
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-
ative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per-
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
 
© The Author(s) 2019
